nach oben

Clinical and Translational Oncology

Erschienen in:

14.08.2017 | Research Article

High expression of HO-1 predicts poor prognosis of ovarian cancer patients and promotes proliferation and aggressiveness of ovarian cancer cells

verfasst von: Z. Zhao, Y. Xu, J. Lu, J. Xue, P. Liu

Erschienen in: Clinical and Translational Oncology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

HO-1 has been proved to be associated with tumor aggressivity and poor prognosis in various cancers. Our study provides the first study to demonstrate the relationship of HO-1 expression and clinical characteristics in ovarian cancer patients.

Methods

Immunohistochemistry and western blotting were used to examine the expression of HO-1 in tissue species and fresh tissues. CCK-8 was used to investigate cell viability. Transwell chamber was performed to estimate migration and invasion capacities in A2780 and Skov-3 cells.

Results

Immunohistochemistry and western blotting showed that the expression of HO-1 was higher in ovarian cancer tissues than normal ovarian tissues. High expression of HO-1 was significantly associated with serous ovarian cancer, high FIGO stage, lymph node metastasis, and non-optimal debulking. Patients with high expression of HO-1 exhibited an unfavorable prognosis. In vitro inducing the expression of HO-1 promoted the proliferation and metastasis of A2780 and Skov-3 cells, with the increased expressions of mesenchymal marker (Vimentin), epithelial–mesenchymal transition-associated transcript factor (Zeb-1), anti-apoptotic protein (Bcl-2), and the decreased expressions of epithelial marker (Keratin) and pro-apoptotic protein (Bax). Meanwhile, after incubating A2780 and Skov-3 together with HO-1 inhibitor, above results could be reversed.

Conclusion

HO-1 might be a potential marker for prediction of ovarian cancer prognosis and a target for ovarian cancer treatment.

Siegel R, Miller K, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.CrossRefPubMed

Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 1988;2(10):2557–68.CrossRefPubMed

Cantoni L, Rossi C, Rizzardini M, Gadina M, Ghezzi P. Interleukin-1 and tumour necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids. Biochem J. 1991;279(Pt 3):891–4.CrossRefPubMedPubMedCentral

Rizzardini M, Terao M, Falciani F, Cantoni L. Cytokine induction of haem oxygenase mRNA in mouse liver. Interleukin 1 transcriptionally activates the haem oxygenase gene. Biochem J. 1993;290(Pt 2):343–7.CrossRefPubMedPubMedCentral

Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, et al. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem. 1997;272(9):5375–81.CrossRefPubMed

Lee J, Lee SK, Lee BU, Lee HJ, Cho NP, Yoon JH, et al. Upregulation of heme oxygenase-1 in oral epithelial dysplasias. Int J Oral Maxillofac Surg. 2008;37(3):287–92. doi:10.1016/j.ijom.2007.07.028.CrossRefPubMed

Nuhn P, Kunzli BM, Hennig R, Mitkus T, Ramanauskas T, Nobiling R, et al. Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo. Mol Cancer. 2009;8:37. doi:10.1186/1476-4598-8-37.CrossRefPubMedPubMedCentral

Kang KA, Maeng YH, Zhang R, Yang YR, Piao MJ, Kim KC, et al. Involvement of heme oxygenase-1 in Korean colon cancer. Tumour Biol J Int Soc Oncodev Biol Med. 2012;33(4):1031–8. doi:10.1007/s13277-012-0336-0.CrossRef

Gandini NA, Fermento ME, Salomon DG, Obiol DJ, Andres NC, Zenklusen JC, et al. Heme oxygenase-1 expression in human gliomas and its correlation with poor prognosis in patients with astrocytoma. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35(3):2803–15. doi:10.1007/s13277-013-1373-z.CrossRef

10.

Yin H, Fang J, Liao L, Maeda H, Su Q. Upregulation of heme oxygenase-1 in colorectal cancer patients with increased circulation carbon monoxide levels, potentially affects chemotherapeutic sensitivity. BMC Cancer. 2014;14:436. doi:10.1186/1471-2407-14-436.CrossRefPubMedPubMedCentral

11.

Wang TY, Liu CL, Chen MJ, Lee JJ, Pun PC, Cheng SP. Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in thyroid cancer. Histopathology. 2015;66(3):447–56. doi:10.1111/his.12562.CrossRefPubMed

12.

Cheng CC, Guan SS, Yang HJ, Chang CC, Luo TY, Chang J, et al. Blocking heme oxygenase-1 by zinc protoporphyrin reduces tumor hypoxia-mediated VEGF release and inhibits tumor angiogenesis as a potential therapeutic agent against colorectal cancer. J Biomed Sci. 2016;23:18. doi:10.1186/s12929-016-0219-6.CrossRefPubMedPubMedCentral

13.

Li CG, Pu MF, Li CZ, Gao M, Liu MX, Yu CZ, et al. MicroRNA-1304 suppresses human non-small cell lung cancer cell growth in vitro by targeting heme oxygenase-1. Acta Pharmacol Sin. 2016;. doi:10.1038/aps.2016.92.

14.

Mayerhofer M, Florian S, Krauth MT, Aichberger KJ, Bilban M, Marculescu R, et al. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Can Res. 2004;64(9):3148–54.CrossRef

15.

Chau LY. Heme oxygenase-1: emerging target of cancer therapy. J Biomed Sci. 2015;22:22. doi:10.1186/s12929-015-0128-0.CrossRefPubMedPubMedCentral

16.

Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, et al. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis. 2003;6(1):15–24.CrossRefPubMed

17.

Gueron G, De Siervi A, Ferrando M, Salierno M, De Luca P, Elguero B, et al. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol Cancer Res. 2009;7(11):1745–55. doi:10.1158/1541-7786.mcr-08-0325.CrossRefPubMed

18.

Tsai JR, Wang HM, Liu PL, Chen YH, Yang MC, Chou SH, et al. High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. Cell Oncol (Dordr). 2012;35(6):461–71. doi:10.1007/s13402-012-0105-5.CrossRefPubMed

19.

Wegiel B, Gallo D, Csizmadia E, Harris C, Belcher J, Vercellotti GM, et al. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Can Res. 2013;73(23):7009–21. doi:10.1158/0008-5472.can-13-1075.CrossRef

20.

Degese MS, Mendizabal JE, Gandini NA, Gutkind JS, Molinolo A, Hewitt SM, et al. Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. Lung Cancer (Amst Neth). 2012;77(1):168–75. doi:10.1016/j.lungcan.2012.02.016.CrossRef

21.

Lee SS, Yang SF, Tsai CH, Chou MC, Chou MY, Chang YC. Upregulation of heme oxygenase-1 expression in areca-quid-chewing-associated oral squamous cell carcinoma. J Formosan Med Assoc Taiwan yi zhi. 2008;107(5):355–63. doi:10.1016/s0929-6646(08)60100-x.CrossRefPubMed

22.

Becker JC, Fukui H, Imai Y, Sekikawa A, Kimura T, Yamagishi H, et al. Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scand J Gastroenterol. 2007;42(7):852–8. doi:10.1080/00365520701192383.CrossRefPubMed

23.

Yanagawa T, Omura K, Harada H, Nakaso K, Iwasa S, Koyama Y, et al. Heme oxygenase-1 expression predicts cervical lymph node metastasis of tongue squamous cell carcinomas. Oral Oncol. 2004;40(1):21–7.CrossRefPubMed

24.

Joung EJ, Li MH, Lee HG, Somparn N, Jung YS, Na HK, et al. Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target. Antioxid Redox Signal. 2007;9(12):2087–98. doi:10.1089/ars.2007.1827.CrossRefPubMed

25.

Boschetto P, Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, et al. Decreased heme-oxygenase (HO)-1 in the macrophages of non-small cell lung cancer. Lung Cancer (Amst Neth). 2008;59(2):192–7. doi:10.1016/j.lungcan.2007.08.019.CrossRef

26.

Lin PH, Lan WM, Chau LY. TRC8 suppresses tumorigenesis through targeting heme oxygenase-1 for ubiquitination and degradation. Oncogene. 2013;32(18):2325–34. doi:10.1038/onc.2012.244.CrossRefPubMed

27.

Chen GG, Liu ZM, Vlantis AC, Tse GM, Leung BC, van Hasselt CA. Heme oxygenase-1 protects against apoptosis induced by tumor necrosis factor-alpha and cycloheximide in papillary thyroid carcinoma cells. J Cell Biochem. 2004;92(6):1246–56. doi:10.1002/jcb.20157.CrossRefPubMed

28.

Liu YS, Li HS, Qi DF, Zhang J, Jiang XC, Shi K, et al. Zinc protoporphyrin IX enhances chemotherapeutic response of hepatoma cells to cisplatin. World J Gastroenterol WJG. 2014;20(26):8572–82. doi:10.3748/wjg.v20.i26.8572.CrossRefPubMed

29.

Kocanova S, Buytaert E, Matroule JY, Piette J, Golab J, de Witte P, et al. Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. Apoptosis Int J Programm Cell Death. 2007;12(4):731–41. doi:10.1007/s10495-006-0016-x.CrossRef

30.

Cannito S, Novo E, di Bonzo LV, Busletta C, Colombatto S, Parola M. Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal. 2010;12(12):1383–430. doi:10.1089/ars.2009.2737.CrossRefPubMed

Titel: High expression of HO-1 predicts poor prognosis of ovarian cancer patients and promotes proliferation and aggressiveness of ovarian cancer cells
verfasst von: Z. Zhao
Y. Xu
J. Lu
J. Xue
P. Liu
Publikationsdatum: 14.08.2017
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 4/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1738-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

High expression of HO-1 predicts poor prognosis of ovarian cancer patients and promotes proliferation and aggressiveness of ovarian cancer cells

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH

The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients

NFBD1/MDC1 participates in the regulation of proliferation and apoptosis in human laryngeal squamous cell carcinoma

Treatment of childhood astrocytomas with irinotecan and cisplatin

The MTHFR polymorphism affect the susceptibility of HCC and the prognosis of HCC liver transplantation

Validation of the AJCC 8th lung cancer staging system among patients with small cell lung cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie